SyntekaBio,Inc. Logo

SyntekaBio,Inc.

AI drug discovery platform accelerating R&D with supercomputing, SaaS, and pre-made candidates.

226330 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
대전광역시 유성구 국제과학17로 18 -, 대전광역시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

SyntekaBio is an AI-driven drug discovery company that utilizes its proprietary supercomputing infrastructure to accelerate the development of therapeutics. The company's core platform, DeepMatcher®, automates the process of identifying and optimizing drug candidates from hit screening to preclinical lead generation. SyntekaBio offers its technology through several business models: STB LaunchPad, a repository of pre-made, 'off-the-shelf' drug candidates for over 100 disease targets; end-to-end discovery and development services; and a suite of CLOUD-SaaS modules for specific applications like small molecule analysis (Sm-ARS), neoantigen prediction (NEO-ARS), and antibody design (Ab-ARS). This 'factory-like' approach aims to reduce the time and cost of pharmaceutical R&D for its partners.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for SyntekaBio,Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-19 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 64.1 KB
2025-09-15 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 100.9 KB
2025-09-12 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(전환사채권발행결정)
Korean 85.9 KB
2025-09-12 00:00
Share Issue/Capital Change
증권발행결과(자율공시)
Korean 5.6 KB
2025-09-12 00:00
Capital/Financing Update
단기차입금감소결정(자율공시)
Korean 7.0 KB
2025-09-12 00:00
Major Shareholding Notification
최대주주변경을수반하는주식담보제공계약해제ㆍ취소등
Korean 12.4 KB
2025-09-12 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 30.4 KB
2025-09-12 00:00
Registration Form
증권신고서(지분증권) (2025.12)
Korean 2.4 MB

Automate Your Workflow. Get a real-time feed of all SyntekaBio,Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for SyntekaBio,Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Open Up Group Inc. Logo
Provides staffing and outsourcing of engineers for global manufacturing, IT, and construction sectors.
Japan 2154
Optipharm.CO.,LTD Logo
Biotech for animal health and xenotransplantation using genetically engineered pig organs.
South Korea 153710
Organoid-based platforms for drug testing and regenerative therapeutics.
South Korea 476040
Oricon Inc. Logo
Provides entertainment industry data, music charts, web media, and marketing services.
Japan 4800
ORIENTBIO Inc. Logo
Provides animal models & technical services for preclinical R&D to pharma & research institutions.
South Korea 002630
Oryzon Genomics S.A. Logo
Develops epigenetic-based medicines for cancer and central nervous system disorders.
Spain ORY
OSCOTECInc. Logo
A clinical-stage drug discovery company developing innovative medicines for unmet needs.
South Korea 039200
OSE Immunotherapeutics Logo
Develops first-in-class immune therapies for oncology and inflammation, partnering for late-stage.
France OSE
Oxurion NV Logo
Acquires European pharmaceutical subcontractors to build an integrated healthcare services group.
Belgium OXUR
PA Co., Ltd Logo
Offers HR solutions like recruitment media, staffing, and childcare to revitalize local communities.
Japan 4766

Talk to a Data Expert

Have a question? We'll get back to you promptly.